Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands?

Tilray delivered stronger and more diversified growth than Canopy: Q4 net revenue rose 25% YoY to $281.7M, with beverage revenue up 60.9% YoY to $105.6M (cannabis up 5% YoY to $71.5M) and gross margin improving to 32% (+200 bps). Canopy’s fiscal Q1 2027 revenue rose 13% YoY to CA$81.2M with gross margin at 27% (+200 bps), but results were largely cannabis-driven and its balance sheet is pressured by higher net debt (~CA$126M net debt vs Tilray’s ~ $0.7M net debt). The article argues Tilray has better growth capacity via lower net leverage and improving profitability signals (Tilray adjusted EBITDA $61.1M in 2026, +11% YoY), while Canopy continues adjusted EBITDA losses (CAD$3.2M in Q1 fiscal 2027).

Analysis

The real market signal is not "growth" but capital structure quality. In a sector where operating leverage is weak and pricing is still under pressure, the company with cleaner net debt and more external cash-flow sources will keep the right to buy assets, keep shelves, and outlast weaker peers. That creates a second-order winner in TLRY: not because the core cannabis franchise is great, but because it can use beverages/distribution to subsidize optionality while competitors remain trapped in survival mode.

CGC’s larger problem is that even modest growth may not translate into equity value if the balance sheet continues to force dilution or keep lenders in control. In a low-liquidity, low-trust industry, net debt matters more than headline debt; it determines who can survive a bad quarter without issuing stock at the bottom. That makes CGC more vulnerable to any margin miss, working-capital swing, or refinancing event over the next 1-3 quarters, especially if Canadian pricing stays soft.

The contrarian angle is that the "better buy" label on TLRY may already be partly priced in, while the market may still underestimate how much of its reported improvement comes from lower-quality, lower-multiple beverage revenue rather than a durable step-up in cannabis economics. If beverage growth slows or integration costs rise, the multiple can compress quickly because investors are paying for a turnaround narrative, not a fortress balance sheet. The key falsifier for TLRY is any stall in EBITDA progression or renewed cash burn; for CGC, it is a credible path to positive EBITDA without further dilution.

Net: this is a relative-value trade, not a sector-wide bullish call. The cleanest setup is to own the stronger balance sheet and avoid the name with financing overhang, while keeping position size modest because both names remain retail-sensitive and headline-driven.

Key Decisions for Investors

• Long TLRY / short CGC as a 1-3 month relative-value pair; target spread outperformance if the market continues to reward balance-sheet resilience and cash-flow optionality. Exit if CGC announces a credible refinancing or TLRY misses EBITDA guidance.
• If entering outright, buy TLRY only on weakness after earnings or a broad cannabis selloff; the risk/reward is better when volatility is elevated and the stock is already discounting mediocre execution. Use a tight thesis stop if operating cash burn re-accelerates.
• Avoid using CGC as a long until the company proves it can fund growth without dilution; treat any bounce into strength as a short-entry opportunity around financing headlines or equity issuance risk.
• Watch Canadian cannabis names for spread widening versus U.S. alcohol/consumer proxies over the next 1-3 quarters; if beverage revenue continues to outgrow cannabis at TLRY, the stock may deserve a premium, but if not, the multiple can reset fast.
• For more disciplined exposure, consider a call-spread structure on TLRY rather than common stock to limit downside in a name with high retail volatility and weak sector fundamentals.